STADA Arzneimittel AG (STDAF.PK) reported that its fiscal 2012 net income increased to 86.5 million euros from 22.0 million euros last year. Earnings per share was 1.46 euros, up from 0.37 euros in the prior year.
Adjusted net income was 147.9 million euros, compared to 146.6 million euros in the previous year. Adjusted earnings per share improved to 2.50 euros from 2.49 euros in the prior year.
Group sales increased by 7 percent to 1.84 billion euros from the previous year's 1.71 billion euros.
STADA Arzneimittel continues to expect further growth of sales and earnings for 2013 and 2014. The company also backed the long-term view for 2014, that is sales of approximately 2.15 billion euros, at an adjusted level, EBITDA of approximately 430 million euros and net income of approximately 215 million euros at minimum.
The company expects the opportunity for further growth in the Group's adjusted EBITDA in the high single-digit percent area and thereby achieving a new record value for 2013.
For comments and feedback: editorial@rttnews.com